Provided by Tiger Fintech (Singapore) Pte. Ltd.

SILO PHARMA INC.

0.5416
-0.0125-2.26%
Post-market: 0.5401-0.0015-0.28%19:43 EDT
Volume:226.59K
Turnover:124.52K
Market Cap:7.21M
PE:-0.54
High:0.5620
Open:0.5529
Low:0.5401
Close:0.5541
52wk High:3.37
52wk Low:0.3960
Shares:13.32M
Float Shares:13.12M
Volume Ratio:0.26
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0002
EPS(LYR):-1.1936
ROE:-90.03%
ROA:-43.96%
PB:1.47
PE(LYR):-0.45

Loading ...

Silo Pharma Inc. Announces Date for 2025 Annual Shareholders Meeting

Reuters
·
Sep 06

BRIEF-Silo Pharma Secures Australian Patent Covering Licensed Ptsd Drug Candidate Expanding Global Ip Portfolio

Reuters
·
Sep 03

Silo Pharma Inc. Announces Date for 2025 Annual Meeting of Shareholders

Reuters
·
Aug 26

Silo Pharma’s Ptsd Candidate Spc-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(B)(2) Pathway

THOMSON REUTERS
·
Aug 19

Silo Pharma Inc - Spc-15 Intranasal Spray Shows Safety With No Toxicities

THOMSON REUTERS
·
Aug 19

Silo Pharma Inc. Issues 750,000 Shares for Asset Acquisition from MAVS Holdings LLC

Reuters
·
Jul 30

Silo Pharma Inc. Completes Dosing in Safety Study of PTSD Drug SPC-15, Awaits Bioanalytical Results

Reuters
·
Jul 16

Silo Pharma Inc. Awaits Pre-Clinical Data for SPC-15, Plans IND Submission for PTSD Drug in 2025 with Potential Phase 1 Trials by 2026

Reuters
·
Jul 07

Silo Pharma Inc. Faces Nasdaq Non-Compliance Over Minimum Bid Price Rule

Reuters
·
Jul 04

Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment

MT Newswires Live
·
Jun 25

BRIEF-Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics

Reuters
·
Jun 25

Silo Pharma Inc. Announces USPTO Notice of Allowance for Biomarker Patent on Novel PTSD Therapeutic SPC-15

Reuters
·
Jun 11

Silo Pharma Inc. Board Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset for Long-Term Value Optimization

Reuters
·
Jun 05

Eric Weisblum, CEO of Silo Pharma Inc., Reports Acquisition of Common Shares

Reuters
·
May 29

Silo Pharma Collaborates With Resyca for Drug-Device Study of PTSD Drug SPC-15

MT Newswires Live
·
May 21

Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission

Reuters
·
May 21

BRIEF-Silo Pharma Announces Closing Of $2 Million Public Offering

Reuters
·
May 17

Silo Pharma Inc. Completes $2 Million Public Offering of Common Stock and Warrants

Reuters
·
May 17

Silo Pharma Announces $2 Million Public Offering of Shares and Warrants

Reuters
·
May 15

Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15

Reuters
·
May 15